DocMorris targets EBITDA break-even in 2026 with new revenue guidance

DocMorris reported FY2025 adjusted EBITDA of CHF -50m (within guidance of -48m to -52m) and ended 2025 with CHF 120m cash. Management guides FY2026 adjusted EBITDA of CHF -10m to -25m (mid-point ~13% above consensus), expects external sales growth mid-single-digit to low-teens, and reiterated an ~8% medium-term EBITDA margin while lowering medium-term revenue growth to ~15% (from 20%) and reducing capex to ~CHF30m. Operationally H2 2025 gross profit rose 18% YoY with a 22.1% margin; Q4 revenue was CHF 331m (+15% reported) and H2 adjusted EBITDA improved to CHF -19m (-3.3% margin). Management targets EBITDA break-even in 2026 and free cash flow break-even in 2027 as prescription and Teleclinic contributions scale.

Analysis

DocMorris’s trajectory is less about a one-time operating beat and more about execution of a multi-channel prescription funnel (online Rx + telemedicine). The critical second-order lever is unit economics on acquired prescription customers: if incremental contribution from teleclinic lifts lifetime value by even a small percentage, the company converts modest revenue growth into disproportionate margin expansion because fulfillment and marketing are semi-fixed. That implies investors should track cohort-level gross margin and repeat-purchase metrics rather than headline revenue or EBITDA in isolation.

Competitive dynamics in German pharmacy are bifurcating: scale players that own both distribution and digital front-ends gain negotiating leverage with suppliers and lower per-prescription logistics cost, while mid-size incumbents face margin compression and become acquisition targets. Faster-growing competitors with higher prescription growth create two flows — talent and pricing pressure — that can accelerate M&A or force defensive pricing, compressing near-term profitability despite headline optimism.

Key near-term catalysts are cadence and quality of prescription roll-up (new vs. existing patients), telehealth conversion rates, and any guidance on unit economics; regulatory changes around reimbursement or pharmacy margins are tail risks that would materially rerate the story. On a multi-quarter horizon, the trade pivots on whether operating leverage materializes as forecast; absent sustained improvement in repeat purchase rates and supplier terms, the path to durable free-cash generation is at risk. Separately, the macro/tech angle (NVDA/TSLA) suggests persistent semi demand that supports a broader risk-on allocation to data-center-exposed names, but that thesis is orthogonal and should be funded selectively from cyclically exposed consumer positions.

Key Decisions for Investors

• Long DOCM (SIX:DOCM) — 6–12 month horizon, small-to-size position: accumulate into post-catalyst weakness and hold while management publishes cohort-level metrics. Risk/reward: asymmetric — limited downside in a buyout or consolidation scenario; primary risks are regulatory or worsening unit economics. Use a 12–18% stop-loss from entry to limit drawdown.
• Pair trade — Long NVDA (NVDA) 12–18 month LEAP calls (buy-dated calls) funded by selling near-term TSLA (TSLA) calls. Rationale: capture secular datacenter GPU upside while monetizing near-term premium in a more volatile auto name. Expect outsized upside if data-center demand persists; downside if semiconductor cycle rolls over or Tesla execution surprises to the upside.
• Event-driven short/hedge for regional pharmacy peers — buy put protection on a European healthcare/retail ETF or short a basket of mid-cap pharmacy operators into any M&A-driven rerating. This hedges exposure to a scenario where DocMorris and a few scale players compress margins across the sector. Timeframe: 3–9 months ahead of next regulatory windows.
• Monitor and act on operational signals rather than price — set alerts for (1) sequential change in repeat prescription rates, (2) teleclinic-to-prescription conversion improvement, and (3) supplier credit terms. If any two metrics deteriorate over two consecutive quarters, reduce equity exposure by 50% and rotate into NVDA/other secular tech names.